Common Splendor International Health Industry Group Limited provided earnings guidance for the six months ended June 30, 2018. For the six months, the company is expected to record an increase of not less than 100% in profit as compared to that of the corresponding period in 2017 of approximately HKD 5.5 million. The expected increase in profit for the Interim Period is mainly attributable to an increase in revenue and gross profit of the medical anti-aging business for the Interim Period, a fair value gain on derivative financial liabilities arising from the redemption of a convertible bond during the Interim Period and a decrease in income tax expense for the Interim Period. The expected increase in profit for the Interim Period is partially offset by the Group's expected decrease in other income, increase in administrative expenses, decrease in share of results of associates and increase in finance cost, for the Interim Period.